Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NANO-X IMAGING LTD.

(NNOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nanox to Host Business Update Video Presentation

08/12/2021 | 08:35am EDT

NEVE ILAN, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that the Company will host a Business Update Video Presentation on Monday, August 16th at 8:30 am ET with Ran Poliakine, Chairman and Chief Executive Officer and other members of Nanox’s senior leadership.

Video Presentation details:

Monday, August 16th
8:30am ET
https://media.rampard.com/202108162/

Interested parties can register for the presentation here.        

About Nanox:

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements contained in this press release that are not historical facts are forward-looking statements and you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. This includes any statements relating to the initiation, timing, progress and results of Nanox's potential acquisitions, research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.ARC.

Forward-looking statements are based on information Nanox has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the negotiations and any subsequent definitive agreements with respect to the proposed acquisitions, and the possibility that the terms and conditions set forth in any definitive agreements with respect to the proposed acquisitions may differ materially from the terms and conditions set forth in the term sheet, (2) the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed acquisitions and any definitive agreements with respect thereto, (3) the inability to complete the proposed transactions, including due to failure to obtain approval of the stockholders of Zebra Medical Vision or other conditions to closing, (4) the impact of the COVID-19 pandemic on the parties’ ability to negotiate and consummate the proposed acquisitions, (5) the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the proposed transactions, (6) the risk that the proposed transaction disrupts current plans and operations as a result of the announcement and consummation of the proposed transaction, (7) the ability to recognize the anticipated benefits of the proposed transactions, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees, (8) costs related to the proposed transactions, (9) the demand for the combined company’s services together with the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors, (10) Nanox's (i) ability to successfully demonstrate the feasibility of its technology for commercial applications; (ii) expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iii) ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (iv) the market acceptance of the Nanox.ARC and the proposed pay-per-scan business model; (v) expectations regarding collaborations with third-parties and their potential benefits; (vi) ability to conduct business globally, and (11) risks and business interruptions related to the COVID-19 pandemic, among others. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox's actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2020 and subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this video clip to conform these statements to actual results or to changes in Nanox's expectations.

Company Contact:

Tamar Aharon Cohen
Nanox Imaging
IR@nanox.vision

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com


Primary Logo


ę GlobeNewswire 2021
All news about NANO-X IMAGING LTD.
01:06pTHE LAW OFFICES OF FRANK R. CRUZ : Announces the Filing of a Securities Class Action on Be..
BU
01:01pDEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming Deadline i..
BU
10/14GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces the Filing of..
BU
10/13NANO X IMAGING : ROSEN, A TOP RANKED LAW FIRM, Encourages Nano-X Imaging Ltd. Investors wi..
BU
10/13INVESTOR ALERT : Law Offices of Howard G. Smith Announces the Filing of a Securities Class..
BU
10/13THE LAW OFFICES OF FRANK R. CRUZ : Announces Investigation of Nano-X Imaging Ltd. (NNOX) o..
BU
10/13GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Investigation..
BU
10/13NANO-X IMAGING LTD. CLASS ACTION ALE : Wolf Haldenstein Adler Freeman & Herz LLP announces..
PR
10/12INVESTOR ALERT : Law Offices of Howard G. Smith Announces Investigation of Nano-X Imaging ..
BU
10/09NANO X IMAGING : ROSEN, A LEADING LAW FIRM, Encourages Nano-X Imaging Ltd. Investors with ..
PR
More news
Analyst Recommendations on NANO-X IMAGING LTD.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -56,6 M - -
Net cash 2021 154 M - -
P/E ratio 2021 -19,2x
Yield 2021 -
Capitalization 1 106 M 1 106 M -
EV / Sales 2021 -
EV / Sales 2022 90,8x
Nbr of Employees 50
Free-Float 77,1%
Chart NANO-X IMAGING LTD.
Duration : Period :
Nano-X Imaging Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANO-X IMAGING LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 22,73 $
Average target price 42,25 $
Spread / Average Target 85,9%
EPS Revisions
Managers and Directors
Ran Poliakine Chairman & Chief Executive Officer
Ran Daniel Chief Financial Officer
Ofir Koren Chief Technology Officer
Uri Shimon Vice President-Information Systems & Technology
James Dara Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NANO-X IMAGING LTD.-50.22%1 106
SONOSCAPE MEDICAL CORP.41.88%2 291
BEIJING WANDONG MEDICAL TECHNOLOGY CO., LTD.88.24%1 662
RAY CO., LTD.11.07%329
VIEWORKS CO., LTD.33.77%319
SDI GROUP PLC57.32%255